CLOs on the Move


 
Kurion creates technological solutions to minimize and stabilize nuclear and hazardous waste for safe, secure and permanent disposal.  Kurion’s suite of waste separation, stabilization and robotic technologies are complemented by engineering and environmental services that together provide an execution platform to service the world’s largest nuclear and hazardous waste sites. Backed by venture capital firms Lux Capital, Firelake Capital and Acadia Woods Partners, the Kurion executive team employs a collective 150 years of industry experience managing nuclear and hazardous waste for commercial and government sites worldwide. Kurion is based in Irvine, Calif., and operates a technology development center at its radioactive materials licensed ...
  • Number of Employees: 250-1000
  • Annual Revenue: > $1 Billion
  • www.kurion.com
  • 2020 Main St. Suite 300
    Irvine, CA USA 92614
  • Phone: 949.398.6350

Executives

Name Title Contact Details

Similar Companies

Hohenstein Institute America

Hohenstein Institute America, Inc is a Elon, NC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Adicet Bio

Adicet Bio, Inc. is a publicly held biotechnology company (Nasdaq: ACET) discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like targeting moieties to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients.

Matthew Gibbs

CipherBio@SVB: Search life science fundraising news and data to discover innovative companies backed by venture investors https://t.co/mmTCuwa0Mc

DSM PTG

DSM PTG, Inc is a Berkeley, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Apogee Therapeutics

Apogee Therapeutics is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and other inflammatory and immunology indications with high unmet need. Apogee`s antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. The company`s two most advanced programs are APG777 and APG808, which are being initially developed for the treatment of AD and COPD, respectively. Based on a broad pipeline and depth of expertise, the company believes it can deliver value and meaningful benefit to patients underserved by today`s standard of care.